Celgene looks to AI company Exscientia to speed up small molecule discovery

Two months after backing Exscientia in a series B round, Celgene signed a three-year deal with the AI company to discover small molecules for three of Celgene's oncology and autoimmunity programs.

Exscientia Ltd. (Oxford, U.K.) said Thursday it will use its AI-driven Centaur Chemist drug discovery platform to identify small molecules within each therapeutic area. CFO Georgy Egorov told BioCentury Exscientia is responsible for delivery of the entire program from gene to preclinical candidate, and Celgene Corp. (NASDAQ:CELG) has opt-in rights. Additional details are undisclosed...